{"transactions":[{"id":4640663,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":85.76,"value":8576.0,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":170000,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640662,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":2451,"price":84.9992,"value":208333.0392,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":169900,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640661,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":2449,"price":84.0707,"value":205889.1443,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":167449,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640660,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":85.76,"value":8576.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":745588,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640659,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":2470,"price":84.9992,"value":209948.024,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":745488,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4640658,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-14T22:58:14.000Z","date":"2026-10-14","kind":"purchase","planned":false,"acquired":true,"shares":2470,"price":84.0707,"value":207654.629,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":743018,"source":{"system":"sec-edgar","filing":"0001366074-26-000006","document":"wk-form4_1792018692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000006/wk-form4_1792018692.xml","form_type":"4"}},{"id":4627828,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:47:30.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":101.702,"value":305106.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were purchased in multiple transactions at prices ranging from $101.44 to $101.80 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":740548,"source":{"system":"sec-edgar","filing":"0001366074-26-000004","document":"wk-form4_1790632047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000004/wk-form4_1790632047.xml","form_type":"4"}},{"id":4627827,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:47:30.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":98.8803,"value":148320.45,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $98.69 to $99.21 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":737548,"source":{"system":"sec-edgar","filing":"0001366074-26-000004","document":"wk-form4_1790632047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000004/wk-form4_1790632047.xml","form_type":"4"}},{"id":4627826,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:47:30.000Z","date":"2026-09-25","kind":"purchase","planned":false,"acquired":true,"shares":2176,"price":99.5988,"value":216726.9888,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $99.335 to $100.00 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":736048,"source":{"system":"sec-edgar","filing":"0001366074-26-000004","document":"wk-form4_1790632047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000004/wk-form4_1790632047.xml","form_type":"4"}},{"id":4627825,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:47:30.000Z","date":"2026-09-25","kind":"purchase","planned":false,"acquired":true,"shares":3324,"price":98.8659,"value":328630.2516,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $98.27 to $99.26 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":733872,"source":{"system":"sec-edgar","filing":"0001366074-26-000004","document":"wk-form4_1790632047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000004/wk-form4_1790632047.xml","form_type":"4"}},{"id":4625569,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-23T20:59:17.000Z","date":"2026-09-23","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":100,"value":500000.0,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":434360,"source":{"system":"sec-edgar","filing":"0001366268-26-000011","document":"wk-form4_1790197155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136626826000011/wk-form4_1790197155.xml","form_type":"4"}},{"id":4622916,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41288,"kind":"person","name":"FORSYTH DOUGLAS","position":1,"cik":"0001240801","reported_name":"FORSYTH DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-18T20:26:27.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."}],"balance_after":10000,"derivative":{"exercise_price":95.22,"exercise_date":"2027-06-03","expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001240801-26-000006","document":"wk-form4a_1789763184.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000124080126000006/wk-form4a_1789763184.xml","form_type":"4/A","original_submission_date":"2026-06-04"}},{"id":4622912,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41223,"kind":"person","name":"Vuori Kristiina MD","position":1,"cik":"0001612627","reported_name":"Vuori Kristiina MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-18T20:25:40.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."}],"balance_after":10000,"derivative":{"exercise_price":95.22,"exercise_date":"2027-06-03","expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001612627-26-000007","document":"wk-form4a_1789763137.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000161262726000007/wk-form4a_1789763137.xml","form_type":"4/A","original_submission_date":"2026-06-04"}},{"id":4622891,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-18T20:22:27.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."}],"balance_after":10000,"derivative":{"exercise_price":95.22,"exercise_date":"2027-06-03","expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001202094-26-000009","document":"wk-form4a_1789762944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202094/000120209426000009/wk-form4a_1789762944.xml","form_type":"4/A","original_submission_date":"2026-06-04"}},{"id":4622888,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-18T20:20:29.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."}],"balance_after":10000,"derivative":{"exercise_price":95.22,"exercise_date":"2027-06-03","expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001366268-26-000009","document":"wk-form4a_1789762826.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136626826000009/wk-form4a_1789762826.xml","form_type":"4/A","original_submission_date":"2026-06-04"}},{"id":4621820,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:46:50.000Z","date":"2026-09-16","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":100,"value":500000.0,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":429360,"source":{"system":"sec-edgar","filing":"0001366268-26-000006","document":"wk-form4_1789681608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136626826000006/wk-form4_1789681608.xml","form_type":"4"}},{"id":4618519,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T21:52:57.000Z","date":"2026-09-15","kind":"sale","planned":false,"acquired":false,"shares":500,"price":105.05,"value":52525.0,"ownership":{"direct":false,"nature":"Kimberly Joan Manhard Revocable Trust,  Dtd 6/4/2012"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001202094-26-000006","document":"wk-form4_1789509175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000120209426000006/wk-form4_1789509175.xml","form_type":"4"}},{"id":4618518,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T21:52:57.000Z","date":"2026-09-14","kind":"sale","planned":false,"acquired":false,"shares":500,"price":110.26,"value":55130.0,"ownership":{"direct":false,"nature":"Kimberly Joan Manhard Revocable Trust,  Dtd 6/4/2012"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001202094-26-000006","document":"wk-form4_1789509175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000120209426000006/wk-form4_1789509175.xml","form_type":"4"}},{"id":4618517,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T21:52:57.000Z","date":"2026-09-11","kind":"sale","planned":false,"acquired":false,"shares":500,"price":111.775,"value":55887.5,"ownership":{"direct":false,"nature":"Kimberly Joan Manhard Revocable Trust,  Dtd 6/4/2012"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012."}],"balance_after":8500,"source":{"system":"sec-edgar","filing":"0001202094-26-000006","document":"wk-form4_1789509175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000120209426000006/wk-form4_1789509175.xml","form_type":"4"}},{"id":4615202,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T23:06:02.000Z","date":"2026-09-09","kind":"sale","planned":false,"acquired":false,"shares":500,"price":115.795,"value":57897.5,"ownership":{"direct":false,"nature":"Kimberly Joan Manhard Revocable Trust,  Dtd 6/4/2012"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012."}],"balance_after":9000,"source":{"system":"sec-edgar","filing":"0001202094-26-000004","document":"wk-form4_1789081560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000120209426000004/wk-form4_1789081560.xml","form_type":"4"}},{"id":4615201,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T23:06:02.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":500,"price":115.14,"value":57570.0,"ownership":{"direct":false,"nature":"Kimberly Joan Manhard Revocable Trust,  Dtd 6/4/2012"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0001202094-26-000004","document":"wk-form4_1789081560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000120209426000004/wk-form4_1789081560.xml","form_type":"4"}},{"id":3552287,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T21:23:30.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":113.516,"value":567580.0,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $113.30 to $113.55 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":424360,"source":{"system":"sec-edgar","filing":"0001366268-26-000004","document":"wk-form4_1788902607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136626826000004/wk-form4_1788902607.xml","form_type":"4"}},{"id":3523721,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41288,"kind":"person","name":"FORSYTH DOUGLAS","position":1,"cik":"0001240801","reported_name":"FORSYTH DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T20:26:03.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":114.6469,"value":286617.25,"ownership":{"direct":false,"nature":"By the Forsyth Family Trust Dated July 20, 2001"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $114.36 to $114.689 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001."}],"balance_after":227064,"source":{"system":"sec-edgar","filing":"0001240801-26-000004","document":"wk-form4_1788899160.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000124080126000004/wk-form4_1788899160.xml","form_type":"4"}},{"id":3513058,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":9681,"price":112.2819,"value":1087001.0739,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares were purchased in multiple transactions at prices ranging from $112.15 to $112.44 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":730548,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513057,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":1219,"price":111.8805,"value":136382.3295,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were purchased in multiple transactions at prices ranging from $111.15 to $112.07 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":720867,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513056,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":108.235,"value":54117.5,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were purchased in multiple transactions at prices ranging from $108.05 to $108.66 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":719648,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513055,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":1100,"price":107.1239,"value":117836.29,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $106.6225 to $107.57 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":719148,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513054,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":6605,"price":100.6388,"value":664719.274,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $100.095 to $100.99 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":718048,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":3513053,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:04:45.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":5895,"price":99.2948,"value":585342.846,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $98.88 to $99.8316 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":711443,"source":{"system":"sec-edgar","filing":"0001366074-26-000002","document":"wk-form4_1788897881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000136607426000002/wk-form4_1788897881.xml","form_type":"4"}},{"id":749148,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41223,"kind":"person","name":"Vuori Kristiina MD","position":1,"cik":"0001612627","reported_name":"Vuori Kristiina MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-04T21:29:14.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."}],"balance_after":15000,"derivative":{"exercise_price":95.22,"exercise_date":"2027-06-03","expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001612627-26-000004","document":"wk-form4_1780608551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612627/000161262726000004/wk-form4_1780608551.xml","form_type":"4"}},{"id":749321,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-04T21:29:06.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."}],"balance_after":15000,"derivative":{"exercise_price":95.22,"exercise_date":"2027-06-03","expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001366268-26-000002","document":"wk-form4_1780608544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000136626826000002/wk-form4_1780608544.xml","form_type":"4"}},{"id":749402,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41288,"kind":"person","name":"FORSYTH DOUGLAS","position":1,"cik":"0001240801","reported_name":"FORSYTH DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-04T21:28:55.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."}],"balance_after":15000,"derivative":{"exercise_price":95.22,"exercise_date":"2027-06-03","expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001240801-26-000002","document":"wk-form4_1780608533.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1240801/000124080126000002/wk-form4_1780608533.xml","form_type":"4"}},{"id":749376,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-04T21:28:48.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."}],"balance_after":15000,"derivative":{"exercise_price":95.22,"exercise_date":"2027-06-03","expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001202094-26-000002","document":"wk-form4_1780608525.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202094/000120209426000002/wk-form4_1780608525.xml","form_type":"4"}},{"id":799789,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":51125,"kind":"person","name":"Matly David","position":1,"cik":"0002062665","reported_name":"Matly David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-27T20:48:53.000Z","date":"2026-04-24","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on April 24, 2027, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":129.06,"expiration_date":"2036-04-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0002062665-26-000002","document":"wk-form4_1777322930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000206266526000002/wk-form4_1777322930.xml","form_type":"4"}},{"id":1020996,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":74386,"kind":"organization","name":"VIKING GLOBAL INVESTORS LP","position":1,"cik":"0001103804","reported_name":"VIKING GLOBAL INVESTORS LP","relationship":{"ten_percent_owner":true}},{"id":74387,"kind":"organization","name":"Viking Global Opportunities Parent GP LLC","position":2,"cik":"0001886738","reported_name":"Viking Global Opportunities Parent GP LLC","relationship":{"ten_percent_owner":true}},{"id":74388,"kind":"organization","name":"Viking Global Opportunities GP LLC","position":3,"cik":"0001629476","reported_name":"Viking Global Opportunities GP LLC","relationship":{"ten_percent_owner":true}},{"id":74389,"kind":"organization","name":"Viking Global Opportunities Portfolio GP LLC","position":4,"cik":"0001629472","reported_name":"Viking Global Opportunities Portfolio GP LLC","relationship":{"ten_percent_owner":true}},{"id":74390,"kind":"organization","name":"Viking Global Opportunities Illiquid Investments Sub-Master LP","position":5,"cik":"0001629482","reported_name":"Viking Global Opportunities Illiquid Investments Sub-Master LP","relationship":{"ten_percent_owner":true}},{"id":74391,"kind":"person","name":"HALVORSEN OLE ANDREAS","position":6,"cik":"0001133006","reported_name":"HALVORSEN OLE ANDREAS","relationship":{"ten_percent_owner":true}},{"id":74392,"kind":"person","name":"Ott David C.","position":7,"cik":"0001621842","reported_name":"Ott David C.","relationship":{"ten_percent_owner":true}},{"id":74393,"kind":"person","name":"Shabet Rose Sharon","position":8,"cik":"0001711393","reported_name":"Shabet Rose Sharon","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-10-09T20:41:40.000Z","date":"2025-10-07","kind":"sale","planned":false,"acquired":false,"shares":25042,"price":32.25,"value":807604.5,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP (\"VGI\"), and Viking Global Opportunities Parent GP LLC (\"Opportunities Parent\"), the sole member of Viking Global Opportunities GP LLC (\"Opportunities GP\"), the sole member of Viking Global Opportunities Portfolio GP LLC (\"Opportunities Portfolio GP\"), the general partner of Viking Global Opportunities Illiquid Investments Sub-Master LP (\"Opportunities Fund\"). Opportunities Parent is also the sole member of Viking Global Opportunities Drawdown GP LLC (\"VGOD GP\"), the sole member of Viking Global Opportunities Drawdown Portfolio GP LLC (\"VGOD Portfolio GP\"), the general partner of Viking Global Opportunities Drawdown (Aggregator) LP (\"VGOD\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"VGI provides managerial services to various investment funds and vehicles, including Opportunities Fund, VGOD, and KAVRA 104 LLC (\"KAVRA 104\"). VGI, Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, Mr. Halvorsen, Mr. Ott and Ms. Shabet are, collectively, the \"Reporting Persons.\" Each of VGI, Mr. Halvorsen, Mr. Ott and Ms. Shabet may be deemed to beneficially own all of the securities reported on this form."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of Common Stock are held directly by VGOD. Because of the relationship between Opportunities Parent and VGOD, Opportunities Parent may be deemed to beneficially own the shares of Common Stock held directly by VGOD."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":102864,"source":{"system":"sec-edgar","filing":"0000905148-25-003555","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1103804/000090514825003555/form4.xml","form_type":"4"}},{"id":1020995,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":74386,"kind":"organization","name":"VIKING GLOBAL INVESTORS LP","position":1,"cik":"0001103804","reported_name":"VIKING GLOBAL INVESTORS LP","relationship":{"ten_percent_owner":true}},{"id":74387,"kind":"organization","name":"Viking Global Opportunities Parent GP LLC","position":2,"cik":"0001886738","reported_name":"Viking Global Opportunities Parent GP LLC","relationship":{"ten_percent_owner":true}},{"id":74388,"kind":"organization","name":"Viking Global Opportunities GP LLC","position":3,"cik":"0001629476","reported_name":"Viking Global Opportunities GP LLC","relationship":{"ten_percent_owner":true}},{"id":74389,"kind":"organization","name":"Viking Global Opportunities Portfolio GP LLC","position":4,"cik":"0001629472","reported_name":"Viking Global Opportunities Portfolio GP LLC","relationship":{"ten_percent_owner":true}},{"id":74390,"kind":"organization","name":"Viking Global Opportunities Illiquid Investments Sub-Master LP","position":5,"cik":"0001629482","reported_name":"Viking Global Opportunities Illiquid Investments Sub-Master LP","relationship":{"ten_percent_owner":true}},{"id":74391,"kind":"person","name":"HALVORSEN OLE ANDREAS","position":6,"cik":"0001133006","reported_name":"HALVORSEN OLE ANDREAS","relationship":{"ten_percent_owner":true}},{"id":74392,"kind":"person","name":"Ott David C.","position":7,"cik":"0001621842","reported_name":"Ott David C.","relationship":{"ten_percent_owner":true}},{"id":74393,"kind":"person","name":"Shabet Rose Sharon","position":8,"cik":"0001711393","reported_name":"Shabet Rose Sharon","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-10-09T20:41:40.000Z","date":"2025-10-07","kind":"sale","planned":false,"acquired":false,"shares":16315,"price":32.25,"value":526158.75,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP (\"VGI\"), and Viking Global Opportunities Parent GP LLC (\"Opportunities Parent\"), the sole member of Viking Global Opportunities GP LLC (\"Opportunities GP\"), the sole member of Viking Global Opportunities Portfolio GP LLC (\"Opportunities Portfolio GP\"), the general partner of Viking Global Opportunities Illiquid Investments Sub-Master LP (\"Opportunities Fund\"). Opportunities Parent is also the sole member of Viking Global Opportunities Drawdown GP LLC (\"VGOD GP\"), the sole member of Viking Global Opportunities Drawdown Portfolio GP LLC (\"VGOD Portfolio GP\"), the general partner of Viking Global Opportunities Drawdown (Aggregator) LP (\"VGOD\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"VGI provides managerial services to various investment funds and vehicles, including Opportunities Fund, VGOD, and KAVRA 104 LLC (\"KAVRA 104\"). VGI, Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, Mr. Halvorsen, Mr. Ott and Ms. Shabet are, collectively, the \"Reporting Persons.\" Each of VGI, Mr. Halvorsen, Mr. Ott and Ms. Shabet may be deemed to beneficially own all of the securities reported on this form."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of Common Stock are held directly by KAVRA 104. The membership interests of KAVRA 104 are held by Viking Global Opportunities LP and Viking Global Opportunities Intermediate LP. Opportunities GP is the general partner of Viking Global Opportunities LP and Viking Global Opportunities Intermediate LP. Because of the relationship between Opportunities GP, Opportunities Parent and KAVRA 104, each of Opportunities GP and Opportunities Parent may be deemed to beneficially own the shares of Common Stock held directly by KAVRA 104."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":67018,"source":{"system":"sec-edgar","filing":"0000905148-25-003555","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103804/000090514825003555/form4.xml","form_type":"4"}},{"id":1020994,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":74386,"kind":"organization","name":"VIKING GLOBAL INVESTORS LP","position":1,"cik":"0001103804","reported_name":"VIKING GLOBAL INVESTORS LP","relationship":{"ten_percent_owner":true}},{"id":74387,"kind":"organization","name":"Viking Global Opportunities Parent GP LLC","position":2,"cik":"0001886738","reported_name":"Viking Global Opportunities Parent GP LLC","relationship":{"ten_percent_owner":true}},{"id":74388,"kind":"organization","name":"Viking Global Opportunities GP LLC","position":3,"cik":"0001629476","reported_name":"Viking Global Opportunities GP LLC","relationship":{"ten_percent_owner":true}},{"id":74389,"kind":"organization","name":"Viking Global Opportunities Portfolio GP LLC","position":4,"cik":"0001629472","reported_name":"Viking Global Opportunities Portfolio GP LLC","relationship":{"ten_percent_owner":true}},{"id":74390,"kind":"organization","name":"Viking Global Opportunities Illiquid Investments Sub-Master LP","position":5,"cik":"0001629482","reported_name":"Viking Global Opportunities Illiquid Investments Sub-Master LP","relationship":{"ten_percent_owner":true}},{"id":74391,"kind":"person","name":"HALVORSEN OLE ANDREAS","position":6,"cik":"0001133006","reported_name":"HALVORSEN OLE ANDREAS","relationship":{"ten_percent_owner":true}},{"id":74392,"kind":"person","name":"Ott David C.","position":7,"cik":"0001621842","reported_name":"Ott David C.","relationship":{"ten_percent_owner":true}},{"id":74393,"kind":"person","name":"Shabet Rose Sharon","position":8,"cik":"0001711393","reported_name":"Shabet Rose Sharon","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-10-09T20:41:40.000Z","date":"2025-10-07","kind":"sale","planned":false,"acquired":false,"shares":308643,"price":32.25,"value":9953736.75,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP (\"VGI\"), and Viking Global Opportunities Parent GP LLC (\"Opportunities Parent\"), the sole member of Viking Global Opportunities GP LLC (\"Opportunities GP\"), the sole member of Viking Global Opportunities Portfolio GP LLC (\"Opportunities Portfolio GP\"), the general partner of Viking Global Opportunities Illiquid Investments Sub-Master LP (\"Opportunities Fund\"). Opportunities Parent is also the sole member of Viking Global Opportunities Drawdown GP LLC (\"VGOD GP\"), the sole member of Viking Global Opportunities Drawdown Portfolio GP LLC (\"VGOD Portfolio GP\"), the general partner of Viking Global Opportunities Drawdown (Aggregator) LP (\"VGOD\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"VGI provides managerial services to various investment funds and vehicles, including Opportunities Fund, VGOD, and KAVRA 104 LLC (\"KAVRA 104\"). VGI, Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, Mr. Halvorsen, Mr. Ott and Ms. Shabet are, collectively, the \"Reporting Persons.\" Each of VGI, Mr. Halvorsen, Mr. Ott and Ms. Shabet may be deemed to beneficially own all of the securities reported on this form."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of Common Stock are held directly by Opportunities Fund. Because of the relationship between Opportunities Portfolio GP, Opportunities GP, Opportunities Parent and Opportunities Fund, each of Opportunities Portfolio GP, Opportunities GP and Opportunities Parent may be deemed to beneficially own the securities held directly by Opportunities Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":1267823,"source":{"system":"sec-edgar","filing":"0000905148-25-003555","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103804/000090514825003555/form4.xml","form_type":"4"}},{"id":1130374,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-29T20:35:52.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on May 28, 2026, subject to the reporting person's continued service through such date."}],"balance_after":15000,"derivative":{"exercise_price":12.91,"exercise_date":"2026-05-28","expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002007919-25-000072","document":"wk-form4_1748550943.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202094/000200791925000072/wk-form4_1748550943.xml","form_type":"4"}},{"id":1130219,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41223,"kind":"person","name":"Vuori Kristiina MD","position":1,"cik":"0001612627","reported_name":"Vuori Kristiina MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-29T20:32:20.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on May 28, 2026, subject to the reporting person's continued service through such date."}],"balance_after":15000,"derivative":{"exercise_price":12.91,"exercise_date":"2026-05-28","expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002007919-25-000070","document":"wk-form4_1748550731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612627/000200791925000070/wk-form4_1748550731.xml","form_type":"4"}},{"id":1130343,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-29T20:27:56.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on May 28, 2026, subject to the reporting person's continued service through such date."}],"balance_after":15000,"derivative":{"exercise_price":12.91,"exercise_date":"2026-05-28","expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002007919-25-000068","document":"wk-form4_1748550471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791925000068/wk-form4_1748550471.xml","form_type":"4"}},{"id":1130388,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41288,"kind":"person","name":"FORSYTH DOUGLAS","position":1,"cik":"0001240801","reported_name":"FORSYTH DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-29T20:24:59.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will be fully exercisable on May 28, 2026, subject to the reporting person's continued service through such date."}],"balance_after":15000,"derivative":{"exercise_price":12.91,"exercise_date":"2026-05-28","expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002007919-25-000066","document":"wk-form4_1748550291.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1240801/000200791925000066/wk-form4_1748550291.xml","form_type":"4"}},{"id":1182205,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":51125,"kind":"person","name":"Matly David","position":1,"cik":"0002062665","reported_name":"Matly David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T20:34:34.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on April 1, 2026, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":14.05,"expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0002007919-25-000035","document":"wk-form4_1743626065.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000035/wk-form4_1743626065.xml","form_type":"4"}},{"id":1182365,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":81200,"kind":"person","name":"Deck Kelly","position":1,"cik":"0001819427","reported_name":"Deck Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T16:39:28.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on April 1, 2026, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":15000,"derivative":{"exercise_price":14.05,"expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002007919-25-000037","document":"wk-form4_1743626285.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819427/000200791925000037/wk-form4_1743626285.xml","form_type":"4"}},{"id":1188700,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:37:18.000Z","date":"2025-03-27","kind":"gift","planned":false,"acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a gift of 90,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's adult children not residing in the reporting person's household, and to which the reporting person does not have a beneficial interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":419360,"source":{"system":"sec-edgar","filing":"0002007919-25-000025","document":"wk-form4_1743197832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791925000025/wk-form4_1743197832.xml","form_type":"4"}},{"id":1328252,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-17T21:29:56.000Z","date":"2024-12-16","kind":"gift","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Paige Gates-Kayyem Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the transfer for no consideration of shares of Common Stock from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the Jon Faiz Kayyem Revocable Trust and the Paige-Gates Kayyem Revocable Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly owned by the Paige-Gates Kayyem Revocable Trust, of which Jon Faiz Kayyem's spouse is the trustee."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0002007919-24-000068","document":"wk-form4_1734470990.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000068/wk-form4_1734470990.xml","form_type":"4"}},{"id":1328251,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-17T21:29:56.000Z","date":"2024-12-16","kind":"gift","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Jon Faiz Kayyem Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the transfer for no consideration of shares of Common Stock from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the Jon Faiz Kayyem Revocable Trust and the Paige-Gates Kayyem Revocable Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by the Jon Faiz Kayyem Revocable Trust, of which Jon Faiz Kayyem is the trustee."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0002007919-24-000068","document":"wk-form4_1734470990.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000068/wk-form4_1734470990.xml","form_type":"4"}},{"id":1328250,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-17T21:29:56.000Z","date":"2024-12-16","kind":"gift","planned":false,"acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the transfer for no consideration of shares of Common Stock from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the Jon Faiz Kayyem Revocable Trust and the Paige-Gates Kayyem Revocable Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":509360,"source":{"system":"sec-edgar","filing":"0002007919-24-000068","document":"wk-form4_1734470990.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000068/wk-form4_1734470990.xml","form_type":"4"}},{"id":1340220,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-06T21:51:12.000Z","date":"2024-12-06","kind":"gift","planned":false,"acquired":false,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a gift of 52,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's adult children not residing in the reporting person's household, and to which the reporting person does not have a beneficial interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":1009360,"source":{"system":"sec-edgar","filing":"0002007919-24-000066","document":"wk-form4_1733521865.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000066/wk-form4_1733521865.xml","form_type":"4"}},{"id":1353909,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T21:03:55.000Z","date":"2024-11-20","kind":"purchase","planned":false,"acquired":true,"shares":18750,"price":14.1921,"value":266101.875,"ownership":{"direct":false,"nature":"By Child B"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $13.93 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":69843,"source":{"system":"sec-edgar","filing":"0002007919-24-000064","document":"wk-form4_1732309427.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000064/wk-form4_1732309427.xml","form_type":"4"}},{"id":1353908,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T21:03:55.000Z","date":"2024-11-20","kind":"purchase","planned":false,"acquired":true,"shares":18750,"price":14.1921,"value":266101.875,"ownership":{"direct":false,"nature":"By Child A"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $13.93 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":69843,"source":{"system":"sec-edgar","filing":"0002007919-24-000064","document":"wk-form4_1732309427.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000064/wk-form4_1732309427.xml","form_type":"4"}},{"id":1353907,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T21:03:55.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":34843,"price":14.2269,"value":495707.8767,"ownership":{"direct":false,"nature":"By Child B"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":51093,"source":{"system":"sec-edgar","filing":"0002007919-24-000064","document":"wk-form4_1732309427.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000064/wk-form4_1732309427.xml","form_type":"4"}},{"id":1353906,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T21:03:55.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":34843,"price":14.2269,"value":495707.8767,"ownership":{"direct":false,"nature":"By Child A"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":51093,"source":{"system":"sec-edgar","filing":"0002007919-24-000064","document":"wk-form4_1732309427.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000064/wk-form4_1732309427.xml","form_type":"4"}},{"id":1389917,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41223,"kind":"person","name":"Vuori Kristiina MD","position":1,"cik":"0001612627","reported_name":"Vuori Kristiina MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-07T20:34:17.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":6667,"price":15,"value":100005.0,"ownership":{"direct":true},"balance_after":20443,"source":{"system":"sec-edgar","filing":"0002007919-24-000051","document":"wk-form4_1728333250.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612627/000200791924000051/wk-form4_1728333250.xml","form_type":"4"}},{"id":1406455,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-16T17:12:34.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":13037,"price":17.13,"value":223323.81,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $16.70 to $17.695, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":705548,"source":{"system":"sec-edgar","filing":"0002007919-24-000049","document":"wk-form4_1726521147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000049/wk-form4_1726521147.xml","form_type":"4"}},{"id":1406454,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-16T17:12:34.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":26963,"price":15.05,"value":405793.15,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":692511,"source":{"system":"sec-edgar","filing":"0002007919-24-000049","document":"wk-form4_1726521147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000049/wk-form4_1726521147.xml","form_type":"4"}},{"id":1408337,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41223,"kind":"person","name":"Vuori Kristiina MD","position":1,"cik":"0001612627","reported_name":"Vuori Kristiina MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-12T21:14:23.000Z","date":"2024-09-11","kind":"purchase","planned":false,"acquired":true,"shares":6457,"price":15.07,"value":97306.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.08, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":13776,"source":{"system":"sec-edgar","filing":"0002007919-24-000047","document":"wk-form4_1726175657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612627/000200791924000047/wk-form4_1726175657.xml","form_type":"4"}},{"id":1408336,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41223,"kind":"person","name":"Vuori Kristiina MD","position":1,"cik":"0001612627","reported_name":"Vuori Kristiina MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-12T21:14:23.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":179,"price":15,"value":2685.0,"ownership":{"direct":true},"balance_after":7319,"source":{"system":"sec-edgar","filing":"0002007919-24-000047","document":"wk-form4_1726175657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612627/000200791924000047/wk-form4_1726175657.xml","form_type":"4"}},{"id":1410655,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-10T17:00:58.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":8500,"price":15.19,"value":129115.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $15.01 to $15.26, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":665548,"source":{"system":"sec-edgar","filing":"0002007919-24-000045","document":"wk-form4_1726002051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000045/wk-form4_1726002051.xml","form_type":"4"}},{"id":1410654,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-10T17:00:58.000Z","date":"2024-09-09","kind":"purchase","planned":false,"acquired":true,"shares":9500,"price":15.21,"value":144495.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $15.08 to $15.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":657048,"source":{"system":"sec-edgar","filing":"0002007919-24-000045","document":"wk-form4_1726002051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000045/wk-form4_1726002051.xml","form_type":"4"}},{"id":1410653,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-10T17:00:58.000Z","date":"2024-09-06","kind":"purchase","planned":false,"acquired":true,"shares":26000,"price":15.29,"value":397540.0,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $15.04 to $15.70, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":647548,"source":{"system":"sec-edgar","filing":"0002007919-24-000045","document":"wk-form4_1726002051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000045/wk-form4_1726002051.xml","form_type":"4"}},{"id":1417432,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41223,"kind":"person","name":"Vuori Kristiina MD","position":1,"cik":"0001612627","reported_name":"Vuori Kristiina MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-03T20:27:44.000Z","date":"2024-08-29","kind":"purchase","planned":false,"acquired":true,"shares":7140,"price":14,"value":99960.0,"ownership":{"direct":true},"balance_after":7140,"source":{"system":"sec-edgar","filing":"0001739614-24-000035","document":"wk-form4_1725395257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612627/000173961424000035/wk-form4_1725395257.xml","form_type":"4"}},{"id":1417511,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-03T17:31:03.000Z","date":"2024-09-03","kind":"purchase","planned":false,"acquired":true,"shares":4712,"price":16.31,"value":76852.72,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were purchased in multiple transactions at prices ranging from $16.115 to $16.465, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":165000,"source":{"system":"sec-edgar","filing":"0001739614-24-000037","document":"wk-form4_1725399057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961424000037/wk-form4_1725399057.xml","form_type":"4"}},{"id":1417510,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-03T17:31:03.000Z","date":"2024-09-03","kind":"purchase","planned":false,"acquired":true,"shares":15288,"price":15.66,"value":239410.08,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $15.115 to $16.11, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":160288,"source":{"system":"sec-edgar","filing":"0001739614-24-000037","document":"wk-form4_1725399057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961424000037/wk-form4_1725399057.xml","form_type":"4"}},{"id":1417509,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-03T17:31:03.000Z","date":"2024-08-30","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":14.02,"value":140200.0,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $13.96 to $14.13, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":145000,"source":{"system":"sec-edgar","filing":"0001739614-24-000037","document":"wk-form4_1725399057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961424000037/wk-form4_1725399057.xml","form_type":"4"}},{"id":1417508,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-03T17:31:03.000Z","date":"2024-08-29","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":14.03,"value":140300.0,"ownership":{"direct":false,"nature":"By Lappe Descendants' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $13.9079 to $14.245, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":135000,"source":{"system":"sec-edgar","filing":"0001739614-24-000037","document":"wk-form4_1725399057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000173961424000037/wk-form4_1725399057.xml","form_type":"4"}},{"id":1418875,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-30T20:16:36.000Z","date":"2024-08-28","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":13.98,"value":139800.0,"ownership":{"direct":false,"nature":"Kimberly Joan Manhard Revocable Trust,  Dtd 6/4/2012"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $13.925 to $14.04, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the  Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0002007919-24-000042","document":"wk-form4_1725048989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202094/000200791924000042/wk-form4_1725048989.xml","form_type":"4"}},{"id":1423144,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41288,"kind":"person","name":"FORSYTH DOUGLAS","position":1,"cik":"0001240801","reported_name":"FORSYTH DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T20:26:53.000Z","date":"2024-08-23","kind":"purchase","planned":false,"acquired":true,"shares":59812,"price":14.07,"value":841554.84,"ownership":{"direct":false,"nature":"By the Forsyth Family Trust Dated July 20, 2001"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $13.48 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001."}],"balance_after":224564,"source":{"system":"sec-edgar","filing":"0002007919-24-000040","document":"wk-form4_1724704006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1240801/000200791924000040/wk-form4_1724704006.xml","form_type":"4"}},{"id":1423143,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41288,"kind":"person","name":"FORSYTH DOUGLAS","position":1,"cik":"0001240801","reported_name":"FORSYTH DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T20:26:53.000Z","date":"2024-08-22","kind":"purchase","planned":false,"acquired":true,"shares":15188,"price":12.89,"value":195773.32,"ownership":{"direct":false,"nature":"By the Forsyth Family Trust Dated July 20, 2001"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $12.80 to $13.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001."}],"balance_after":164752,"source":{"system":"sec-edgar","filing":"0002007919-24-000040","document":"wk-form4_1724704006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1240801/000200791924000040/wk-form4_1724704006.xml","form_type":"4"}},{"id":1425080,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-22T16:29:47.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":12945,"price":12.93,"value":167378.85,"ownership":{"direct":false,"nature":"The Mark Paul Lappe Roth IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were purchased in multiple transactions at prices ranging from $12.82 to $13.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":54865,"source":{"system":"sec-edgar","filing":"0002007919-24-000038","document":"wk-form4_1724358581.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000038/wk-form4_1724358581.xml","form_type":"4"}},{"id":1425079,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-22T16:29:47.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":27055,"price":12.97,"value":350903.35,"ownership":{"direct":false,"nature":"The Mark Paul Lappe Roth IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $12.77 to $13.14, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":41920,"source":{"system":"sec-edgar","filing":"0002007919-24-000038","document":"wk-form4_1724358581.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000200791924000038/wk-form4_1724358581.xml","form_type":"4"}},{"id":1470450,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-24T21:27:15.000Z","date":"2024-06-24","kind":"gift","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Child B"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction involved a gift of 10,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a custodial account managed by the reporting person for the benefit of the\nreporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":16250,"source":{"system":"sec-edgar","filing":"0002007919-24-000024","document":"wk-form4_1719264429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000024/wk-form4_1719264429.xml","form_type":"4"}},{"id":1470449,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-24T21:27:15.000Z","date":"2024-06-24","kind":"gift","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Child A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction involved a gift of 10,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a custodial account managed by the reporting person for the benefit of the\nreporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":16250,"source":{"system":"sec-edgar","filing":"0002007919-24-000024","document":"wk-form4_1719264429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000024/wk-form4_1719264429.xml","form_type":"4"}},{"id":1470448,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-24T21:27:15.000Z","date":"2024-06-24","kind":"gift","planned":false,"acquired":false,"shares":89050,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a gift of 89,050 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's children, relatives, and other individuals. Of the shares gifted, 40,000 shares were gifted to the reporting person's adult children not residing in the reporting person's household, 22,825 shares were gifted to trusts for the benefit of individuals not residing in the reporting person's household, 4,150 shares were gifted to relatives not residing in the reporting person's household, and 2,075 shares were gifted to a UTMA for the benefit of a minor not residing in the reporting person's household, in each case to which the reporting person does not have a beneficial interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims\nbeneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":1061360,"source":{"system":"sec-edgar","filing":"0002007919-24-000024","document":"wk-form4_1719264429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000024/wk-form4_1719264429.xml","form_type":"4"}},{"id":1486310,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T22:05:13.000Z","date":"2024-06-05","kind":"purchase","planned":false,"acquired":true,"shares":8265,"price":17.89,"value":147860.85,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were purchased in multiple transactions at prices ranging from $17.81 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1150410,"source":{"system":"sec-edgar","filing":"0002007919-24-000008","document":"wk-form4_1717797906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000008/wk-form4_1717797906.xml","form_type":"4"}},{"id":1486309,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T22:05:13.000Z","date":"2024-06-05","kind":"purchase","planned":false,"acquired":true,"shares":49284,"price":17.23,"value":849163.32,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $16.81 to $17.805, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1142145,"source":{"system":"sec-edgar","filing":"0002007919-24-000008","document":"wk-form4_1717797906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000008/wk-form4_1717797906.xml","form_type":"4"}},{"id":1491626,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T21:27:32.000Z","date":"2024-06-04","kind":"purchase","planned":false,"acquired":true,"shares":23726,"price":18.24,"value":432762.24,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1092861,"source":{"system":"sec-edgar","filing":"0002007919-24-000006","document":"wk-form4_1717536444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000006/wk-form4_1717536444.xml","form_type":"4"}},{"id":1491625,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T21:27:32.000Z","date":"2024-06-04","kind":"purchase","planned":false,"acquired":true,"shares":65337,"price":17.44,"value":1139477.28,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1069135,"source":{"system":"sec-edgar","filing":"0002007919-24-000006","document":"wk-form4_1717536444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000006/wk-form4_1717536444.xml","form_type":"4"}},{"id":1491624,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T21:27:32.000Z","date":"2024-06-03","kind":"purchase","planned":false,"acquired":true,"shares":80738,"price":17.9,"value":1445210.2,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at prices ranging from $17.40 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1003798,"source":{"system":"sec-edgar","filing":"0002007919-24-000006","document":"wk-form4_1717536444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000006/wk-form4_1717536444.xml","form_type":"4"}},{"id":1491623,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T21:27:32.000Z","date":"2024-06-03","kind":"purchase","planned":false,"acquired":true,"shares":46792,"price":16.61,"value":777215.12,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were purchased in multiple transactions at prices ranging from $16.25 to $16.75, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":923060,"source":{"system":"sec-edgar","filing":"0002007919-24-000006","document":"wk-form4_1717536444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000006/wk-form4_1717536444.xml","form_type":"4"}},{"id":1491622,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T21:27:32.000Z","date":"2024-05-31","kind":"purchase","planned":false,"acquired":true,"shares":70193,"price":16.14,"value":1132915.02,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $15.75 to $16.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":876268,"source":{"system":"sec-edgar","filing":"0002007919-24-000006","document":"wk-form4_1717536444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000200791924000006/wk-form4_1717536444.xml","form_type":"4"}},{"id":1496274,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX","position":1,"cik":"0001739614","reported_name":"Inhibrx, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2024-05-31T16:30:04.000Z","date":"2024-05-29","kind":"other","planned":false,"acquired":false,"shares":13316140,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 8, 2024, Inhibrx, Inc. (\"RemainCo\"), acquired 100 shares, par value $0.0001 per share (the \"Common Stock\"), of Inhibrx Biosciences, Inc. (the \"Issuer\"), which at the time constituted all of the issued and outstanding Common Stock of the Issuer. On May 29, 2024, the Common Stock was split, resulting in RemainCo's ownership of an aggregate 14,474,066 shares of Common Stock of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 29, 2024 at 11:59 p.m., New York City time, RemainCo distributed approximately 92% of the Common Stock of the Issuer to the holders of record of RemainCo as of May 17, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 29, 2024 at 11:59 p.m., New York City time, RemainCo distributed approximately 92% of the Common Stock of the Issuer to the holders of record of RemainCo as of May 17, 2024."}],"balance_after":1157926,"source":{"system":"sec-edgar","filing":"0000950170-24-067359","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739614/000095017024067359/ownership.xml","form_type":"4"}},{"id":1497468,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41223,"kind":"person","name":"Vuori Kristiina MD","position":1,"cik":"0001612627","reported_name":"Vuori Kristiina MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T22:11:30.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date."}],"balance_after":30000,"derivative":{"exercise_price":15.86,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950142-24-001495","document":"es240484865_4-vuori.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612627/000095014224001495/es240484865_4-vuori.xml","form_type":"4"}},{"id":1497628,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41279,"kind":"person","name":"MANHARD KIMBERLY","position":1,"cik":"0001202094","reported_name":"MANHARD KIMBERLY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T22:11:10.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date."}],"balance_after":30000,"derivative":{"exercise_price":15.86,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950142-24-001494","document":"es240484864_4-manhard.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202094/000095014224001494/es240484864_4-manhard.xml","form_type":"4"}},{"id":1497594,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T22:10:31.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F5","text":"This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This stock option will be fully exercisable on May 30, 2025, subject to the reporting person?s continued service through such date."}],"balance_after":30000,"derivative":{"exercise_price":15.86,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950142-24-001492","document":"es240484862_4-kayyem.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000095014224001492/es240484862_4-kayyem.xml","form_type":"4"}},{"id":1497593,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-30T22:10:31.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":false,"nature":"By Child B"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0000950142-24-001492","document":"es240484862_4-kayyem.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000095014224001492/es240484862_4-kayyem.xml","form_type":"4"}},{"id":1497592,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-30T22:10:31.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":false,"nature":"By Child A"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0000950142-24-001492","document":"es240484862_4-kayyem.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000095014224001492/es240484862_4-kayyem.xml","form_type":"4"}},{"id":1497591,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41263,"kind":"person","name":"Kayyem Jon Faiz","position":1,"cik":"0001366268","reported_name":"Kayyem Jon Faiz","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-30T22:10:31.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":806075,"ownership":{"direct":false,"nature":"By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein."}],"balance_after":806075,"source":{"system":"sec-edgar","filing":"0000950142-24-001492","document":"es240484862_4-kayyem.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366268/000095014224001492/es240484862_4-kayyem.xml","form_type":"4"}},{"id":1497656,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41288,"kind":"person","name":"FORSYTH DOUGLAS","position":1,"cik":"0001240801","reported_name":"FORSYTH DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T22:10:12.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date."}],"balance_after":30000,"derivative":{"exercise_price":15.86,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950142-24-001491","document":"es240484861_4-forsyth.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1240801/000095014224001491/es240484861_4-forsyth.xml","form_type":"4"}},{"id":1497655,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":41288,"kind":"person","name":"FORSYTH DOUGLAS","position":1,"cik":"0001240801","reported_name":"FORSYTH DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-30T22:10:12.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":149564,"ownership":{"direct":false,"nature":"By the Forsyth Family Trust Dated July 20, 2001"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001."}],"balance_after":149564,"source":{"system":"sec-edgar","filing":"0000950142-24-001491","document":"es240484861_4-forsyth.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1240801/000095014224001491/es240484861_4-forsyth.xml","form_type":"4"}},{"id":1497585,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T18:10:50.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F4","text":"This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter."}],"balance_after":300000,"derivative":{"exercise_price":15.86,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000950142-24-001493","document":"es240484863_4-lappe.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001493/es240484863_4-lappe.xml","form_type":"4"}},{"id":1497584,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:10:50.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":14865,"ownership":{"direct":false,"nature":"The Mark Paul Lappe Roth IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."}],"balance_after":14865,"source":{"system":"sec-edgar","filing":"0000950142-24-001493","document":"es240484863_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001493/es240484863_4-lappe.xml","form_type":"4"}},{"id":1497583,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:10:50.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":125000,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0000950142-24-001493","document":"es240484863_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001493/es240484863_4-lappe.xml","form_type":"4"}},{"id":1497582,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":87508,"kind":"person","name":"Lappe Mark","position":1,"cik":"0001366074","reported_name":"Lappe Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:10:50.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":621548,"ownership":{"direct":false,"nature":"By the Lappe Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust."}],"balance_after":621548,"source":{"system":"sec-edgar","filing":"0000950142-24-001493","document":"es240484863_4-lappe.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366074/000095014224001493/es240484863_4-lappe.xml","form_type":"4"}},{"id":1497439,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":90432,"kind":"person","name":"Eckelman Brendan P.","position":1,"cik":"0001766433","reported_name":"Eckelman Brendan P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T18:09:52.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F5","text":"This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter."}],"balance_after":175000,"derivative":{"exercise_price":15.86,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950142-24-001490","document":"es240484860_4-eckelman.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1766433/000095014224001490/es240484860_4-eckelman.xml","form_type":"4"}},{"id":1497438,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":90432,"kind":"person","name":"Eckelman Brendan P.","position":1,"cik":"0001766433","reported_name":"Eckelman Brendan P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:09:52.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0000950142-24-001490","document":"es240484860_4-eckelman.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1766433/000095014224001490/es240484860_4-eckelman.xml","form_type":"4"}},{"id":1497437,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":90432,"kind":"person","name":"Eckelman Brendan P.","position":1,"cik":"0001766433","reported_name":"Eckelman Brendan P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:09:52.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0000950142-24-001490","document":"es240484860_4-eckelman.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1766433/000095014224001490/es240484860_4-eckelman.xml","form_type":"4"}},{"id":1497436,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":90432,"kind":"person","name":"Eckelman Brendan P.","position":1,"cik":"0001766433","reported_name":"Eckelman Brendan P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-30T18:09:52.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":433888,"ownership":{"direct":false,"nature":"By the Eckelman Living Trust Dated February 5, 2014"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the \"Issuer\"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014."}],"balance_after":433888,"source":{"system":"sec-edgar","filing":"0000950142-24-001490","document":"es240484860_4-eckelman.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766433/000095014224001490/es240484860_4-eckelman.xml","form_type":"4"}},{"id":1497401,"issuer":{"id":4576,"kind":"organization","name":"Inhibrx Biosciences, Inc.","symbol":"INBX"},"owners":[{"id":81200,"kind":"person","name":"Deck Kelly","position":1,"cik":"0001819427","reported_name":"Deck Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T18:09:29.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter."}],"balance_after":175000,"derivative":{"exercise_price":15.86,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950142-24-001489","document":"es240484859_4-deck.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819427/000095014224001489/es240484859_4-deck.xml","form_type":"4"}}]}